IP Library Granted Patent US 12,338,232
Granted Patent B2
US 12,338,232 · App. 18/315,291 · Granted Jun 24, 2025

THRβ receptor agonist compound and preparation method and use thereof

Inventors: Shanghai Yu (Kun Shan, CN); Ben Li (Kun Shan, CN)
Assignee: Terns, Inc.
C07D403/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,338,232
App. No.
18/315,291
Granted
Jun 24, 2025
Kind
B2
Abstract

The present invention discloses a compound represented by the following Formula (I) and a pharmaceutically acceptable salt thereof. The compound improves the THRα selectivity while maintaining good THRβ agonistic activity, thereby improving properties of the finished drug.

Claims (62)

1. A method of synthesizing a compound of Formula (I):

or a pharmaceutically acceptable salt thereof;

wherein:

Ring A is a C 5-10 aliphatic ring or a C 5-10 aromatic ring, each optionally substituted with one or more substituents independently selected from the group consisting of hydrogen, halogen atoms, hydroxy, —OCF 3 , —NH 2 , —NHC 1-4 alkyl, —N(C 1-4 alkyl) 2 , —CONH 2 , —CONHC 1-4 alkyl, —CON(C 1-4 alkyl) 2 , —NHCOC 1-4 alkyl, C 1-6 alkyl, C 1-6 alkoxy, and C 3-6 cycloalkyl, and when two substituents are contained, the two substituents can form a ring structure together with the carbon connected thereto; and the halogen atoms are selected from the group consisting of F, Cl and Br;

R 2 and R 3 are each independently selected from the group consisting of halogen atoms, and substituted or unsubstituted C 1-6 alkyl, the substituent being selected from the group consisting of halogen atoms, hydroxy, and C 1-6 alkoxy; and

R 1 is selected from the group consisting of hydrogen, cyano, substituted or unsubstituted C 1-6 alkyl, and substituted or unsubstituted C 3-6 cycloalkyl, the substituent being selected from the group consisting of halogen atoms, hydroxy, and C 1-6 alkoxy;

comprising a step of contacting a compound of Formula (I-c):

or a salt thereof, with a compound of Formula (I-d):

or a salt thereof, to produce a compound of Formula (I-e):

or a salt thereof.

2. The method of claim 1 , wherein the step of contacting the compound of Formula (I-c) with the compound of Formula (I-d) takes place in the presence of a base.

3. The method of claim 1 , further comprising a step of subjecting the compound of Formula (I-e):

or a salt thereof, to an alkaline or acidic environment at a high temperature to produce a compound of Formula (I-f):

or a salt thereof.

4. The method of claim 3 , wherein the high temperature is greater than 100° C.

5. The method of claim 3 , wherein the alkaline or acidic environment comprises acetic acid and sodium acetate.

6. The method of claim 3 , wherein the alkaline environment comprises sodium hydroxide.

7. The method of claim 1 , further comprising a step of contacting a compound of Formula (I-f):

or a salt thereof, with a compound of Formula I-g:

or a salt thereof, to produce the compound of Formula (I):

or a salt thereof.

8. The method of claim 7 , wherein the step of contacting the compound of Formula (I-f), or a salt thereof, with the compound of Formula (I-g), or a salt thereof, takes place in the presence of a nitrite, in an acidic aqueous solution.

9. The method of claim 8 , wherein the nitrite is sodium nitrite.

10. The method of claim 7 , wherein the acidic aqueous solution comprises hydrochloric acid.

11. The method of claim 7 , wherein the method further comprises contacting with acetic acid and sodium acetate.

12. The method of claim 1 , wherein the compound of Formula (I) is a compound of Formula (II):

wherein,

R 2 and R 3 are each independently selected from the group consisting of halogen atoms and substituted or unsubstituted C 1-6 alkyl, the substituent being selected from the group consisting of halogen atoms, hydroxy, and C 1-6 alkoxy; and

R 1 is selected from the group consisting of hydrogen, cyano, substituted or unsubstituted C 1-6 alkyl, and substituted or unsubstituted C 3-6 cycloalkyl, the substituent being selected from the group consisting of halogen atoms, hydroxy, and C 1-6 alkoxy;

L is not present or is selected from the group consisting of —CH 2 — and —CH 2 CH 2 —;

R 4 is selected from the group consisting of hydrogen, halogen atoms, hydroxy, —OCF 3 , —NH 2 , —NHC 1-4 alkyl, —N(C 1-4 alkyl) 2 , C 1-6 alkyl, C 1-6 alkoxy, and C 3-6 cycloalkyl;

n is an integer from the range 1 to 4;

m is an integer from the range 1 to 4;

when L is not present, the ring may have two or more substituents R 4 thereon; and

the halogen atoms are selected from the group consisting of F, Cl, and Br.

13. The method of claim 12 , wherein:

R 4 is selected from the group consisting of hydrogen and C 1-3 alkyl;

L is not present;

n is 1, 2 or 3; and

m is 1 or 2.

14. The method of claim 12 , wherein:

R 4 is selected from the group consisting of hydrogen and C 1-3 alkyl;

L is —CH 2 — or —CH 2 CH 2 —;

n is 1, 2 or 3; and

m is 1 or 2.

15. The method of claim 1 , wherein Ring A is a C 5-10 aromatic ring optionally substituted with one or more substituents independently selected from the group consisting of hydrogen, halogen atoms, hydroxy, —OCF 3 , —NH 2 , —NHC 1-4 alkyl, —N(C 1-4 alkyl) 2 , —CONH 2 , —CONHC 1-4 alkyl, —CON(C 1-4 alkyl) 2 , —NHCOC 1-4 alkyl, C 1-6 alkyl, C 1-6 alkoxy, and C 3-6 cycloalkyl, and when two substituents are contained, the two substituents can form a ring structure together with the carbon connected thereto; and the halogen atoms are selected from the group consisting of F, Cl, and Br.

16. The method of claim 15 , wherein the compound of Formula (I) is a compound of Formula (III):

wherein:

R 2 and R 3 are each independently selected from the group consisting of halogen atoms and substituted or unsubstituted C 1-6 alkyl, the substituent being selected from the group consisting of halogen atoms, hydroxy, and C 1-6 alkoxy; and

R 1 is selected from the group consisting of hydrogen, cyano, substituted or unsubstituted C 1-6 alkyl, and substituted or unsubstituted C 3-6 cycloalkyl, the substituent being selected from the group consisting of halogen atoms, hydroxy, and C 1-6 alkoxy;

R 4 is selected from the group consisting of hydrogen, halogen atoms, hydroxy, —OCF 3 , —NH 2 , —NHC 1-4 alkyl, —N(C 1-4 alkyl) 2 , —CONH 2 , —CONHC 1-4 alkyl, —CON(C 1-4 alkyl) 2 , —NHCOC 1-4 alkyl, C 1-6 alkyl, C 1-6 alkoxy, and C 3-6 cycloalkyl;

m is an integer from the range 1 to 4; and

the halogen atoms are selected from the group consisting of F, Cl, and Br.

17. The method of claim 16 , wherein R 4 is selected from the group consisting of hydrogen, halogen atoms, hydroxy, —OCF 3 , C 1-6 alkyl, C 1-6 alkoxy, and C 3-6 cycloalkyl; and m is an integer from the range 1 to 3.

18. The method of claim 17 , wherein R 4 is selected from the group consisting of hydrogen, halogen atoms, and C 1-3 alkyl; and m is 1 or 2.

19. The method of claim 18 , wherein R 4 is hydrogen.

20. The method of claim 1 , wherein the compound of Formula (I) is selected from the following compounds:

21. The method of claim 1 , wherein the compound of Formula (I) is selected from the following compounds:

22. The method of claim 1 , wherein the compound of Formula (I) is

23. The method of claim 1 , wherein the compound of Formula (I) is

24. The method of claim 1 , wherein the compound of Formula (I) is

25. The method of claim 1 , wherein the compound of Formula (I) is

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2026
From: TERNS, INC.
To: TERNS PHARMACEUTICALS, INC.
Reel/Frame 073662/0311 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2024
From: YU, SHANGHAI; LI, BEN
To: VINTAGENCE BIOTECHNOLOGY, LTD.
Reel/Frame 068519/0393 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2024
From: VINTAGENCE BIOTECHNOLOGY, LTD.
To: TERNS PHARMACEUTICALS, INC.
Reel/Frame 068519/0402 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2024
From: TERNS PHARMACEUTICALS, INC.
To: TERNS, INC.
Reel/Frame 068519/0405 →
Priority Claims (1)
CN 201811527414.4 · Dec 13, 2018 · national
Continuity (5)
Continuation 17951883 · Sep 23, 2022
Continuation 17675690 · Feb 18, 2022
Continuation 17305302 · Jul 2, 2021
Continuation 16712301 · Dec 12, 2019
Related Publication 20230278988A1 · Sep 7, 2023
References Cited (236)
US 4197307A · Gallay et al. · 1980 [cited by applicant]
US 5114938A · Lindner et al. · 1992 [cited by applicant]
US 6787652B1 · Dow et al. · 2004 [cited by applicant]
US 7807674B2 · Haynes et al. · 2010 [cited by applicant]
US 8153624B2 · Genin et al. · 2012 [cited by applicant]
US 8785408B2 · Feinstein et al. · 2014 [cited by applicant]
US 8791266B2 · Kawata et al. · 2014 [cited by applicant]
US 10208019B2 · Aspnes et al. · 2019 [cited by applicant]
US 10800767B2 · Kirschberg et al. · 2020 [cited by applicant]
US 11034676B2 · Yu et al. · 2021 [cited by applicant]
US 11084802B2 · Yu et al. · 2021 [cited by applicant]
US 11168079B2 · Carpenter et al. · 2021 [cited by applicant]
US 11203587B2 · Kirschberg et al. · 2021 [cited by applicant]
US 11964964B2 · Jin et al. · 2024 [cited by applicant]
US 20030078288A1 · Haning et al. · 2003 [cited by applicant]
US 20040157844A1 · Dow et al. · 2004 [cited by applicant]
US 20050085541A1 · Shiohara et al. · 2005 [cited by applicant]
US 20080167313A1 · Dupont-Passelaigue et al. · 2008 [cited by applicant]
US 20090005383A1 · Haynes et al. · 2009 [cited by applicant]
US 20090247539A1 · Bell et al. · 2009 [cited by applicant]
US 20100004271A1 · Garcia Collazo et al. · 2010 [cited by applicant]
US 20100152166A1 · Genin et al. · 2010 [cited by applicant]
US 20100286182A1 · Samuels et al. · 2010 [cited by applicant]
US 20120129812A1 · Kawata et al. · 2012 [cited by applicant]
US 20140275077A1 · Dandu et al. · 2014 [cited by applicant]
US 20150368205A1 · Ji et al. · 2015 [cited by applicant]
US 20170050949A1 · Dandu et al. · 2017 [cited by applicant]
US 20170334883A1 · Albrecht et al. · 2017 [cited by applicant]
US 20180297987A1 · Coates et al. · 2018 [cited by applicant]
US 20190111012A1 · Hanf · 2019 [cited by applicant]
US 20190247404A1 · Namisaki et al. · 2019 [cited by applicant]
US 20190321364A1 · Satyal et al. · 2019 [cited by applicant]
US 20190352286A1 · Claremon et al. · 2019 [cited by applicant]
US 20200009092A1 · Roberts et al. · 2020 [cited by applicant]
US 20200054589A1 · Noel et al. · 2020 [cited by applicant]
US 20200062742A1 · Kirschberg et al. · 2020 [cited by applicant]
US 20200115362A1 · Kirschberg et al. · 2020 [cited by applicant]
US 20200190064A1 · Yu et al. · 2020 [cited by applicant]
US 20200354345A1 · Vandyck et al. · 2020 [cited by applicant]
US 20200397798A1 · Mohan et al. · 2020 [cited by applicant]
US 20200399249A1 · Yu et al. · 2020 [cited by applicant]
US 20210115022A1 · Jin et al. · 2021 [cited by applicant]
US 20210379040A1 · Fenaux et al. · 2021 [cited by applicant]
US 20210379043A1 · Fenaux et al. · 2021 [cited by applicant]
US 20220135540A1 · Sweetana et al. · 2022 [cited by applicant]
US 20220281849A1 · Kirschberg et al. · 2022 [cited by applicant]
US 20220332707A1 · Du et al. · 2022 [cited by applicant]
US 20220348561A1 · Kirschberg et al. · 2022 [cited by applicant]
US 20220356177A1 · Kirschberg et al. · 2022 [cited by applicant]
US 20230241071A1 · Fenaux et al. · 2023 [cited by applicant]
US 20240000765A1 · Fenaux et al. · 2024 [cited by applicant]
US 20240059682A1 · Kirschberg et al. · 2024 [cited by applicant]
US 20240156826A1 · Taub · 2024 [cited by applicant]
US 20240239761A1 · Zhang et al. · 2024 [cited by applicant]
US 20240293416A1 · Jones et al. · 2024 [cited by applicant]
US 20240316025A1 · Fenaux et al. · 2024 [cited by applicant]
CN 101228135A · 2008 [cited by applicant]
CN 102898377A · 2013 [cited by applicant]
CN 103130723A · 2013 [cited by applicant]
CN 105477636A · 2016 [cited by applicant]
CN 110167557A · 2019 [cited by applicant]
CN 111320609A · 2020 [cited by applicant]
CN 111484481A · 2020 [cited by applicant]
CN 111909137A · 2020 [cited by applicant]
CN 114437034A · 2022 [cited by applicant]
EP 1471049A1 · 2004 [cited by applicant]
EP 3437659A1 · 2019 [cited by applicant]
EP 3807267A1 · 2021 [cited by applicant]
IN 202047050376A · 2020 [cited by applicant]
JP H02225483A · 1990 [cited by applicant]
JP 2001114768A · 2001 [cited by applicant]
JP 2004517851A · 2004 [cited by applicant]
JP 2007512314A · 2007 [cited by applicant]
JP 2009501759A · 2009 [cited by applicant]
JP 2011114768A · 2011 [cited by applicant]
JP 2011528007A · 2011 [cited by applicant]
JP 2017525740A · 2017 [cited by applicant]
JP 2021531325A · 2021 [cited by applicant]
RU 2668960C2 · 2018 [cited by applicant]
WO WO0198256A1 · 2001 [cited by applicant]
WO WO03064369A1 · 2003 [cited by applicant]
WO WO03094845A2 · 2003 [cited by applicant]
WO WO2007003419A1 · 2007 [cited by applicant]
WO WO2007009913A1 · 2007 [cited by applicant]
WO WO2007128492A1 · 2007 [cited by applicant]
WO WO2007134864A1 · 2007 [cited by applicant]
WO WO2009012125A1 · 2009 [cited by applicant]
WO WO2009037172A1 · 2009 [cited by applicant]
WO WO2010006962A1 · 2010 [cited by applicant]
WO WO2010122980A1 · 2010 [cited by applicant]
WO WO2011038207A1 · 2011 [cited by applicant]
WO WO2014043706A1 · 2014 [cited by applicant]
WO WO2016036873A1 · 2016 [cited by applicant]
WO WO2017167935A1 · 2017 [cited by applicant]
WO WO2017170434A1 · 2017 [cited by applicant]
WO WO2018027892A1 · 2018 [cited by applicant]
WO WO2018028517A1 · 2018 [cited by applicant]
WO WO2018073154A1 · 2018 [cited by applicant]
WO WO2018075650A1 · 2018 [cited by applicant]
WO WO2018103624A1 · 2018 [cited by applicant]
WO WO2018153933A1 · 2018 [cited by applicant]
WO WO2018167103A1 · 2018 [cited by applicant]
WO WO2018170173A1 · 2018 [cited by applicant]
WO WO2018193006A1 · 2018 [cited by applicant]
WO WO2018193007A1 · 2018 [cited by applicant]
WO WO2018208707A1 · 2018 [cited by applicant]
WO WO2019023245A1 · 2019 [cited by applicant]
WO WO2019038456A1 · 2019 [cited by applicant]
WO WO2019053233A1 · 2019 [cited by applicant]
WO WO2019053235A1 · 2019 [cited by applicant]
WO WO2019094777A1 · 2019 [cited by applicant]
WO WO2019144835A1 · 2019 [cited by applicant]
WO WO2019240938A1 · 2019 [cited by applicant]
WO WO2020041741A1 · 2020 [cited by applicant]
WO WO2020042114A1 · 2020 [cited by applicant]
WO WO2020061086A2 · 2020 [cited by applicant]
WO WO2020061114A1 · 2020 [cited by applicant]
WO WO2020073974A1 · 2020 [cited by applicant]
WO WO2020077123A1 · 2020 [cited by applicant]
WO WO2020123827A1 · 2020 [cited by applicant]
WO WO2020131578A2 · 2020 [cited by applicant]
WO WO2020169069A1 · 2020 [cited by applicant]
WO WO2020227549A1 · 2020 [cited by applicant]
WO WO2020239076A1 · 2020 [cited by applicant]
WO WO2021014350A1 · 2021 [cited by applicant]
WO WO2021041237A1 · 2021 [cited by applicant]
WO WO2021050945A1 · 2021 [cited by applicant]
WO WO2021121210A1 · 2021 [cited by applicant]
WO WO2021231644A1 · 2021 [cited by applicant]
WO WO2021231646A1 · 2021 [cited by applicant]
WO WO2022152770A1 · 2022 [cited by applicant]
WO WO2022187403A1 · 2022 [cited by applicant]
WO WO2023083288A1 · 2023 [cited by applicant]
WO WO2023086561A1 · 2023 [cited by applicant]
WO WO2023220404A1 · 2023 [cited by applicant]
Bashir, M., et al., “Liver vol. Reduction in Resmetirom Treated Non-Cirrhotic and Cirrhotic NASH Patients,” Hepatology, Oct. 2021, vol. 74, No. 1 (Supplement), pp. 1142A-1143A. [cited by applicant]
Co-pending U.S. Appl. No. 18/818,705, inventors Kirschberg; Thorsten A. et al., filed Aug. 29, 2024. [cited by applicant]
Dennis, A., et al., “Correlations Between MRI Biomarkers PDFF and cT1 with Histopathological Features on Non-Alcoholic Steatohepatitis,” Frontiers in Endocrinology, Jan. 2021, vol. 11, Article 575843, 10 pages. [cited by applicant]
Extended European Search Report and Search Opinion, dated Apr. 2, 2024, for European Patent Application No. 21803928.7, 11 pages. [cited by applicant]
Gallup. Americans' Average Weight Holds Steady in 2020, Jan. 4, 2021, Retrieved from the Internet on Sep. 27, 2023, https://news.gallup.com/poll/328241/americans-average-weight-holds-steady-2020.aspx, 9 pages. [cited by applicant]
Harrison, S. A., et al., “A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis,” The New England Journal of Medicine, Feb. 8, 2024, vol. 390, No. 6, pp. 497-509. [cited by applicant]
Harrison, S. A., et al., “Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial,” Nature Medicine, Nov. 2023, vol. 29, 2919-2928, including additional material, 19… [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2022/049690 mailed May 23, 2024, 12 pages. [cited by applicant]
International Preliminary Report on Patentability, mailed May 23, 2024, for International Application No. PCT/CN2022/131297, 7 pages. [cited by applicant]
Kirschberg, T., et al., “TERN-501, a potent and selective agonist of thyroid hormone receptor beta, strongly reduces histological features and biomarkers of non-alcoholic steatohepatitis associated pathology in rodent m… [cited by applicant]
Loomba, R., et al., Relationship of Non-Invasive Measures with Histological Response in Patients with NonAlcoholic Steatohepatitis and Fibrosis: 52-Week Data from the Phase 3 Maestro-NASH Trial, Hepatology, 2023, 78 (Su… [cited by applicant]
Noureddin, M., et al., “5000 | Topline Results from a 12-Week Phase 2a Trial (Duet) Evaluating Tern-501, A Highly Selective Thyroid Hormone Receptor (THR) Beta Agonist, Either as Monotherapy or in Combination with TERN-… [cited by applicant]
Noureddin, M., et al., “Head-to-Head Comparison of Fast, Mast, MEFIB and cT1 in Identifying At-Risk NASH Patients in a Low-Prevalence Population,” Hepatology, 2023, 78(Supplement 1):S1-S2154, pp. S806-S810, Abstract 205… [cited by applicant]
Rich, N. E., et al., “Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis,” Clinical Gastroenterology and Hepa… [cited by applicant]
Rinella, M. E., et al., “AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease,” Hepatology 2023, 77, 1797-1835. [cited by applicant]
Stine, J. G., et al., “Change in MRI-PDFF and Histologic Response in Patients with Non-alcoholic Steatohepatitis: A Systematic Review and Meta-Analysis,” Clinical Gastroenterology and Hepatology 2021, vol. 19, No. 11, 2… [cited by applicant]
Sumida, Y., et al., “Current and new pharmacotherapy options for non-alcoholic steatohepatitis,” Expert Opinion on Pharmacotherapy, vol. 21, No. 8, Apr. 1, 2020, pp. 953-967, DOI: 10.1080/14656566.2020.1744564. [cited by applicant]
Ashburner M., et al., “Gene Ontology: Tool For The Unification Of Biology. The Gene Ontology Consortium,” Nature Genetics, May 2000, vol. 25, pp. 25-29. [cited by applicant]
Basnak, I. et al. (1975). “Synthesis of 5-cyclopropyl-6-azauracil,” Collect. Czech Chem. Commun. 40(4):1038-1042. [cited by applicant]
Baxter, J. D. et al., “Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes,” Nature Reviews Drug Discovery, vol. 8, No. 4, pp. 308-320 (Apr. 2009). [cited by applicant]
Belikov, V.G, “Pharmaceutical Chemistry. Chapter 2.6 Relationship between the chemical structure, properties of substances and their effect on the body”, MEDpress-inform (2007); pp. 27-29; 14 pages with English translat… [cited by applicant]
Berry, M. J., et al., “Thyroid hormone regulates type I deiodinase messenger RNA in rat liver,” Molecular Endocrinology, 1990, 4:743-748. [cited by applicant]
Brecher, J., “Graphical Representation of Stereochemical Configuration (IUPAC Recommendations 2006),” Pure and Appl. Chem. 78(10):1897-1970 (2006). [cited by applicant]
Chen, H.C. et al. (Nov. 13-16, 2020). MET409, an Optimized Sustained FXR Agonist, Was Safe and Well-Tolerated in a 14-Day Phase 1 Study in Healthy Subjects, Me0.tacrine, 1 page, Poster presented at Poster presentation a… [cited by applicant]
Chung D., et al., “Pharmacokinetics Of Two Oral Formulations Of Liver-directed, Nonsteroidal Farnesoid X-Receptor Agonist Tern-101 In Healhy Volunteers,” Terns Pharmaceutical, Inc., Poster presented at Paris NASH Meetin… [cited by applicant]
Dermer, G.B., “Another Anniversary for the War on Cancer,” Bio/Technology, 12:320, 1 page (Mar. 1994). [cited by applicant]
Dufour J-F., et al., “Combination Therapy For Non-Alcoholic Steatohepatitis: Rationale, Opportunities And Challenges,” Gut, 69(10):1877-1884 (2020). [cited by applicant]
Dunkel, P. et al., “Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1: a patent survey,” Expert Opinion on Therapeutic Patents, Jun. 2011, vol. 21, No. 9, pp. 1453-1471, doi: 10.1517/13543776.2011.594040. [cited by applicant]
Erion, M.D., “Targeting thyroid hormone receptor-β agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index,” PNAS, Sep. 25, 2007, 104(39), 15490-15495. [cited by applicant]
Extended European Search Report and Search Opinion for Application No. 19870196.3, mailed on May 18, 2022, 5 pages. [cited by applicant]
Extended European Search Report and Search Opinion for European Application No. 19852050.4, mailed Mar. 22, 2022, 7 Pages. [cited by applicant]
Extended European Search Report and Search Opinion, mailed Aug. 17, 2023, for European Patent Application No. 20863146.5, 7 pages. [cited by applicant]
Extended European Search Report and Search Opinion, mailed Jul. 6, 2022, for European Application No. 19896475.1 (8 total pages). [cited by applicant]
Extended European Search Report and Search Opinion, mailed Mar. 30, 2023, for European Application No. 20856291.8 (8 total pages). [cited by applicant]
Fiorucci, S., et al., “Future trends in the treatment of nonalcoholic steatohepatitis,” Pharmacological Research, Jul. 2018, vol. 134, pp. 289-298, doi: 10.1016/J.PHRS.2018.07.014. [cited by applicant]
Freshney R.I., et al., “Culture of Animal Cells,” A Manual of Basic Technique, 1983, Alan R. Liss, Inc., New York, p. 4 and pp. 129-133 (9 total pages). [cited by applicant]
Gene Ontology Consortium, Creating the Gene Ontology Resource: Design and Implementation. Genome Research 11: 1425-1433 (2001). [cited by applicant]
Grover, G. J., et al., Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3′-triiodo-L-thyronine, Endocrinology, vol. 145, No. … [cited by applicant]
Han C.Y., “Update on FXR Biology: Promising Therapeutic Target?,” International Journal of Molecular Sciences, Jul. 16, 2018, vol. 19, No. 2069, 25 pages. [cited by applicant]
Hansen, H. H., et al., “Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis,” BMC Gastroenterology (2020), 20:210, pp. 1-12, https://doi.org/10.1186/s12876-020-01356-2. [cited by applicant]
Hennessey, J. V., et al., “The emergence of levothyroxine as a treatment for hypothyroidism,” Endocrine, 2017, 55: 6-18, DOI: 10.1007/s12020-016-1199-8. [cited by applicant]
Hill, S. R. Jr., S et al. (1960). “The Metabolic Effects of the Acetic and Propionic Acid Analogs of Thyroxine and Triiodothyronine,” J Clin. Invest. (39):523-533. [cited by applicant]
Ichiki, T., et al., “Thyroid Hormone and Vascular Remodeling,” Journal of Atherosclerosis and Thrombosis, 2016, vol. 23, No. 3, pp. 266-275. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/CN2018/103349, mailed Mar. 11, 2021, 7 Pages. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2008/069719, mailed Jan. 19, 2010, 7 Pages. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2019/047968, mailed Mar. 11, 2021, 7 Pages. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2019/055689, mailed Apr. 22, 2021, 9 Pages. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2019/066013, mailed Jun. 24, 2021, 6 Pages. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2020/047467, mailed Mar. 3, 2022, 9 Pages. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2020/050497, mailed Mar. 24, 2022, 7 Pages. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2022/018575, mailed Sep. 14, 2023, 18 pages. [cited by applicant]
International Preliminary Report on Patentability, mailed Nov. 24, 2022, for International Application No. PCT/US2021/032085 (12 total pages). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/CN2018/103349, mailed Jun. 5, 2019, 9 Pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/CN2022/131297, mailed on Feb. 10, 2023, 10 pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2008/069719, mailed Nov. 6, 2008, 9 Pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/047968, mailed Nov. 21, 2019, 9 Pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/055689, mailed Jan. 23, 2020, 12 Pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/066013, mailed Feb. 28, 2020, 8 Pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2020/047467, mailed Jan. 15, 2021, 12 Pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2020/050497, mailed Dec. 8, 2020, 9 Pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2020/059522, mailed Feb. 5, 2021, 9 Pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2021/032085, mailed Sep. 30, 2021, 17 Pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2022/049690, mailed Mar. 16, 2023, 21 pages. [cited by applicant]
International Search Report and Written Opinion, mailed Aug. 2, 2023, for International Application No. PCT/US2023/022093, 8 pages. [cited by applicant]
International Search Report and Written Opinion, mailed May 23, 2022, for International Application No. PCT/US2022/018575 (21 total pages). [cited by applicant]
Invitation to Pay Additional Fees, and, Where Applicable, Protest Fee, mailed Jul. 6, 2021, for International Application No. PCT/US2021/032083 (3 total pages). [cited by applicant]
Invitation to Pay Additional Fees, mailed Jul. 6, 2021, for International Application No. PCT/US2021/032085, 3 pages. [cited by applicant]
Invitation to Pay Additional Fees, mailed Nov. 21, 2019, for International Application No. PCT/US2019/055689, 2 pages. [cited by applicant]
Invitation to Pay Additional Fees, mailed Oct. 4, 2020, for International Application No. PCT/US2020/047467, 2 pages. [cited by applicant]
Jones C., et al., “Combination of TERN-101, a Farnesoid X Receptor Agonist, and TERN-501, a Selective Agonist of Thyroid Hormone Receptor Beta, Reduces Activation of Inflammatory and Fibrotic Gene Pathways in a Mouse Mo… [cited by applicant]
Jones, C., et al., EASL, Aug. 28, 2020, Single doses of TERN-201, a novel selective semicarbazide-sensitive amine oxidase (SSAO) inhibitor, are safe, well-tolerated, and result in sustained reduction of SSAO activity in… [cited by applicant]
Jones, C., et al., Single doses of the THR-B agonist TERN-501 are well tolerated and result in dose-dependent changes in LDL cholesterol and sex hormone binding globulin in a first-in-human clinical trial, AASLD, Nov. 1… [cited by applicant]
Kawamata, Y., et al. “AG protein-coupled receptor responsive to bile acids”, The Journal of Biological Chemistry, 278(11):9435-9440 (Mar. 2003). [cited by applicant]
Kelly, M. J., et al., “Discovery of 2-[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6- carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Re… [cited by applicant]
Kim D., et al., “Critical Roles of the Histone Methyltransferase MLL4/KMT2D in Murine Hepatic Steatosis Directed by ABL1 and PPARgamma2,” Cell Reports, 2016, vol. 17(6), pp. 1671-1682, DOI: 10.1016/j.celrep.2016.10.023. [cited by applicant]
Kirschberg, T., et al., EASL, Aug. 29, 2020, “TERN-501, a potent and selective agonist of thyroid hormone receptor beta, strongly reduces histological features and biomarkers of non-alcoholic steatohepatitis associated … [cited by applicant]
Klein, I et al., “Cardiovascular Involvement in General Medical Conditions, Thyroid Disease and the Heart,” Circulation, Oct. 9, 2007, 116:1725-1735. [cited by applicant]
Kleiner, D. E., et al., “Design and validation of a histological scoring system for nonalcoholic fatty liver disease,” Hepatology, Jun. 2005, 41(6):1313-1321. [cited by applicant]
Klucher, K., et al., EASL, Aug. 29, 2020, Anti-inflammatory and anti-fibrotic activity of TERN-201, a semicarbazide-sensitive amine oxidase inhibitor, in a rat choline-deficient high-fat diet non-alcoholic steatohepatit… [cited by applicant]
Kogler, M., “Synthesis and Evaluation of 6-aza-2′-deoxyuridine Monophosphate Analogs as Inhibitors pf Thymidylate Synthases, and as Substrates or Inhibitors of Thymidine Monophosphate Kinase in Mycobacterium tuberculosi… [cited by applicant]
Kowalik et al., “Thyroid Hormones, Thyromimetics and Their Metabolites in the Treatment of Liver Disease,” Frontiers in Endocrinology, vol. 9, Article 382, pp. 1-11 (Jul. 2018). [cited by applicant]
Krchnak, V. et al., “Novel Pyrimidine Derivatives, Reactions and Ultraviolet Spectra,” Collection Czechoslov. Chem. Commun. 1975, vol. 40, pp. 1396-1402. [cited by applicant]
Kremoser C., “Fxr Agonists for NASH: How Are They Different And What Difference Do They Make?,” Journal of Hepatology 2021, vol. 75, pp. 12-15. [cited by applicant]
Liver Meeting Digital Experience 2020, Oct. 14, 2020, https://www.ternspharma.com/1 0-14-20- terns-to-present-positive-data-on-single-agend-and-combo-nash-at-liver-meeting-exp-2020, 3 pages. [cited by applicant]
Loomba, R., et al., “Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data,” Alimentary Pharmacology and The… [cited by applicant]
Nelson, C. H., et al., Multiple Doses of Thyroid Hormone Receptor-Beta Agonist TERN-501 were Well-Tolerated and Resulted in Significant Dose-Dependent Changes in Serum Lipids and Sex Hormone Binding Globulin in a First-… [cited by applicant]
Nelson, C. H., et al., Thyroid Hormone Beta Receptor Agonist Tern-501 Demonstrates Dose- And Exposure-Dependent Increases In Sex Hormone Binding Globulin With Associated Decreases In Atherogenic Lipids In Healthy Subjec… [cited by applicant]
Nelson, R. H., “Hyperlipidemia as a risk factor for cardiovascular disease,” Prim Care Clin Office Pract 40 (2013) 195-211, http://dx.doi.org/10.1016/j.pop.2012.11.003. [cited by applicant]
Obach R.S., et al., “The Prediction Of Human Pharmacokinetic Parameters From Preclinical And In Vitro Metabolism Data,” Journal of Pharmacology and Experimental Therapeutics, 1997, vol. 283, No. 1, pp. 46-58. [cited by applicant]
Pagadala, M. R, et al., “Prevalence of hypothyroidism in nonalcoholic fatty liver disease,” Digestive Diseases and Sciences, 2012, 57:528-534, DOI 10.1007/s10620-011-2006-2. [cited by applicant]
Pubchem (Jan. 12, 2016). “4-(1,2,4-Benzotriazin-3-Yloxy)-N-Methylaniline,” CID: 103204817, 7 pages. [cited by applicant]
Schwimmer, J. B., et al., “Prevalence Of Fatty Liver In Children And Adolescents,” Pediatrics, Oct. 2006, vol. 118, No. 4, pp. 1388-1393. [cited by applicant]
Shepherd, E. L., et al., “Inhibition Of Vascular Adhesion Protein-1 Modifies Hepatic Steatosis In Vitro And In Vivo,” World Journal of Hepatology, Nov. 27, 2020, vol. 12, No. 11, pp. 931-948. [cited by applicant]
Simone, J. V. (1996) “Introduction” in Cecil Textbook of Medicine. 20th Ed., vol. I . J. Claude Bennet and F. Plum (Eds.) W.B. Sauders Co.; pp. 1004-1010. [cited by applicant]
Sinha, R. A. et al., “Direct Effects of Thyroid Hormones on Hepatic Lipid Metabolism,” Nat. Rev. Endocrinology, May 2018, 14(5):259-269 (26 total pages). [cited by applicant]
Taub, R,, et al., ‘Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist,’ Atherosclerosis, 2013, 230:373-380. [cited by applicant]
U.S. Appl. No. 17/305,302, filed Jul. 2, 2021, by Shanghai Yu et al. (The U.S. Patent Application is not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004.). [cited by applicant]
Vuppalanchi, R., et al., “Therapeutic pipeline in nonalcoholic steatohepatitis,” Nature Reviews Gastroenterology, Feb. 2021, vol. 18, No. 6, pp. 373-392, doi: 10.1038/S41575-020-00408-Y. [cited by applicant]
Walenbergh, S. A., et al., “Cholesterol is a significant risk factor for nonalcoholic steatohepatitis,” Expert Review of Gastroenterology & Hepatology 2015, 9(11):1343-1346. [cited by applicant]
Extended European Search Report and Search Opinion, dated Dec. 23, 2024, for European Patent Application No. 22764006.7, 10 pages. [cited by applicant]
International Preliminary Report on Patentability, mailed Nov. 28, 2024, for International Application No. PCT/US2023/022093, 6 pages. [cited by applicant]
Cited By (3)
US 12,459,926 US 12,485,118 US 12,528,791